Prevalence of S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut.

OBJECTIVE: To determine the prevalence of S315T mutation within the katG gene that confers clinically significant resistance to isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from tuberculosis patients in Dubai and Beirut. METHOD: A total of 28 and 17 isoniazid-resistant and seven and six susceptible clinical M. tuberculosis isolates from Dubai and Beirut, respectively, were tested. The presence of S315T mutation in the katG gene was detected by amplification of the DNA region around codon 315 by polymerase chain reaction followed by restriction digestion with Msp I to generate restriction fragment length polymorphism. The genotyping of the isolates carrying S315T mutation was carried out by touchdown double-repetitive-element PCR (DRE-PCR). RESULTS: The mutation S315T was detected in 18 (64%) of 28 isoniazid-resistant isolates from Dubai and in six (35%) of 17 resistant strains from Beirut. None of the susceptible strains contained this mutation. The genotyping studies showed that the majority of the isolates carrying the S315T mutation exhibited unique DNA banding patterns. CONCLUSION: The data show a varying prevalence of S315T mutation within the katG gene in M. tuberculosis strains isolated from the two geographical locations, Dubai and Beirut.     

Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers.

OBJECTIVE: To determine the factors associated with the development of multidrug-resistant tuberculosis among patients at a New York City Hospital and to investigate possible nosocomial transmission. DESIGN: A retrospective case-control study and tuberculin skin test survey. PATIENTS: Twenty-three patients with tuberculosis whose isolates were resistant to at least isoniazid and rifampin (case patients) were compared with patients with tuberculosis whose isolates were susceptible to all agents tested (controls). Tuberculin skin test conversion rates were compared among health care workers assigned to wards where patients with tuberculosis were frequently or rarely admitted. SETTING: A large, teaching hospital in New York City. MEASUREMENTS: Mycobacterium tuberculosis isolates from case patients and controls were typed by restriction fragment length polymorphism analysis. RESULTS: Case patients were younger (median age, 34 compared with 42 years; P = 0.006), more likely to be seropositive for HIV (21 of 23 compared with 11 of 23 patients; odds ratio, 11.5; 95% CI, 1.9 to 117), and more likely to have had a previous hospital admission within 7 months before the onset of tuberculosis (19 of 23 compared with 5 of 23 patients; odds ratio, 17.1; CI, 3.3 to 97), particularly on one ward (12 of 23 compared with 0 of 23 patients; odds ratio, undefined; P = 0.002). Health care workers assigned to wards housing case patients were more likely to have tuberculin skin test conversions than were health care workers assigned to other wards (11 of 32 compared with 1 of 47 health care workers; P less than 0.001). Few (6 of 23) case patients were placed in acid-fast bacilli isolation, and no rooms tested had negative pressure. Of 16 available multidrug-resistant isolates obtained from case patients, 14 had identical banding patterns by restriction fragment length polymorphism analysis. In contrast, M. tuberculosis isolates from controls with drug-susceptible tuberculosis had patterns distinct from each other and from those of case patients. CONCLUSIONS: These data suggest nosocomial transmission of multidrug-resistant tuberculosis occurred from patient to patient and from patient to health care worker and underscore the need for effective acid-fast bacilli isolation facilities and adherence to published infection control guidelines in health care institutions.     

Risk factors for recent transmission of Mycobacterium tuberculosis.

In recent decades, the decline of tuberculosis has stopped in Western Europe, mainly due to increased immigration from high-prevalence countries. The objective of the current study was to identify risk factors for developing tuberculosis following recent infection, in order to better target interventions. Strains from 861 culture-positive cases, diagnosed in Norway in 1994-1999, were analysed by use of restriction fragment length polymorphism (RFLP). A cluster was defined as two or more isolates with identical RFLP patterns. Risk factors for being part of a cluster were identified by univariate and multivariate analysis. A total of 134 patients were part of a cluster. These constituted 5% Asian-born, 18% Norwegian-born, 24% European-born and 29% African-born patients. Four independent risk factors for being part of a cluster were identified: being born in Norway, being of young age, being infected with an isoniazid-resistant strain and being infected with a multidrug-resistant strain. Transmission of tuberculosis may be further reduced by improving case management, contact tracing, preventive treatment, screening of immigrants and access to health services for the foreign-born population.     

多重聚合酶链反应-单链构象多态性分析检测耐异烟肼结核分枝杆菌

目的　建立耐异烟肼 (isoniazid ,INH )结核分枝杆菌多重聚合酶链反应 单链构象多态性分析 (multiple polymerasechainreaction singlestrandconformationpolymorphism ,multi PCR SSCP)方法 ,快速、特异地同时检出aphC启动子、inhA、katG基因的突变情况 ,用于快速诊断结核分枝杆菌对INH的耐药性。方法　根据结核分枝杆菌的aphC启动子序列、inhA序列、katG序列 ,分别设计出 3对特异性寡聚核苷酸引物 ,采用multi PCR及SSCP技术 ,同时检测对结核分枝杆菌耐INH起作用的这 3个基因的突变情况。结果　对H3 7Rv标准株、临床分离INH敏感株 (2 3株 )及INH耐药株 (3 5株 )分别采用常规PCR和multi PCR同时进行扩增 ,两种扩增方法均能扩增出预期的目的片段 ,且结果符合率达10 0 % ;采用单基因PCR SSCP ,aphC启动子序列突变检出率 17% (6/3 5)、inhA序列突变检出率 2 0 % (7/3 5)、katG序列突变检出率 66% (2 3 /3 5) ;multi PCR SSCP突变检出率 83 % (2 9/3 5)。结论　耐药基因检测指导治疗是一种新探索 ,multi PCR SSCP方法敏感、特异 ,能同时快速有效地检测结核分枝杆菌aphC启动子、inhA、katG 3个INH耐药基因的突变 ,提高检验效率 ,有望成为临床指导用药的好方法。     

Characterization of drug-resistant isolates of Mycobacterium tuberculosis derived from Russian inmates.

SETTING: Tuberculosis ward of a prison in Russia. OBJECTIVE: Molecular characterization of drug-resistant isolates. DESIGN: Isolates were collected from all tuberculosis patients occurring in the prison over a 1-year period. RESULTS: Of 130 patients studied, 17 patients produced pan-susceptible isolates and 113 produced isolates resistant to at least one drug, including 85 multidrug-resistant isolates. Mutations at katG315 occurred in 98% of isoniazid-resistant isolates. Mutations in rpoB were found in 89% of rifampicin-resistant isolates. Mutations in pncA occurred in 13% of the 75 isolates tested. By spoligotyping, members of the Beijing (55 isolates) and LAM (31 isolates) families were identified. By IS6110 genotyping, two groups (34 and 55 isolates) of related isolates were found, including three clusters (10, 12, and 16 isolates) with identical patterns. In a study of samples collected 3 months apart from 28 patients, four patients produced isolates containing a mixture of strains and five patients produced specimens containing distinctly different isolates. Isolates of nine patients acquired additional drug resistance. CONCLUSION: Three families of strains accounted for much of the drug-resistant tuberculosis in this population. Multiple resistance, acquisition of resistance, and infection with two or more strains as well as reinfection were observed.     

耐异烟肼结核分枝杆菌临床分离株耐药相关基因突变研究

目的阐明结核分枝杆菌耐异烟肼临床分离株katG、inhA、ahpC、kasA及oxyR基因突变特点。方法对144株结核分枝杆菌临床分离株(耐异烟肼菌株101株;异烟肼敏感株43株)的katG、inhA、kasA、ahpC及oxyR基因进行DNA片断扩增及DNA序列分析,与GeneBank中结核分枝杆菌标准序列进行比较。结果(1)耐异烟肼菌株中未发现katG完全缺失,81株耐药株(80.2%)katG存在点突变、缺失或插入,其中16个突变位点未见报道;39株(38.6%)耐药株第315位点突变,低耐药菌株(1μg/ml)第315位点突变率显著高于高耐药菌株(10μg/ml;χ2=9.31,P<0.05);58株(57.4%)耐药株第463位点突变。23株(53.3%)敏感株第463位点突变。(2)5株(4.9%)耐药株inhA发生突变。敏感株inhA无突变。(3)3株(2.9%)耐药株ahpC发生突变。敏感株ahpC无突变。(4)17株(16.8%)耐药株kasA发生突变。敏感株中3株菌株Gly312Ser突变。(5)在全部菌株中未发现oxyR基因突变。(6)综合本项研究中各基因的突变情况,共有91株耐异烟肼菌株发生与异烟肼耐药相关的突变。结论本项研究进一步证实了结核分枝杆菌耐异烟肼与katG、inhA、ahpC及kasA基因突变之间的关系,并且提示还有其他机制参与异烟肼耐药。     

结核分支杆菌异烟肼耐药基因突变微通道电泳检测方法的建立

目的 建立一种用微通道电泳芯片分析系统检测结核分支杆菌异烟肼耐药基因突变的方法。方法 以丙烯酰胺及其衍生物的聚合物溶液作为筛分介质，溶液中掺入微量的吖啶橙作为荧光标记物，对结核分支杆菌的异烟肼耐药相关的katG和inhA基因进行单链构象多态性(SSCP)分析，检测其与耐药性相关的突变。对于突变部位附近没有二级结构的inhA基因，设计了特别的引物使扩增产物增加一个能与突变部位配对的区域，从而使野生型片段呈现独特的构象。结果 此方法可实现对katG基因野生型片段与315位密码子突变型片段的区分，以及对inhA基因调节序列野生型与突变型片段的区分。30个临床分离株中的23个耐药株有22个被检出，效率达95％。结论 微通道电泳方法用于结核杆菌耐药基因突变检测，具有快速、灵敏的优点，可望将之应用于临床耐药性检测。     

Molecular characterization of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Kazakhstan

Kazakhstan is one of the 14 countries with a high rate of morbidity due to multidrug-resistant tuberculosis (MDR TB) in WHO European region. The aim of our study was to characterize mutations associated with drug resistance to rifampicin and isoniazid in Mycobacterium tuberculosis isolates from Kazakhstan. M. tuberculosis strains were isolated from TB patients in different regions of Kazakhstan. A drug susceptibility test was performed on Lowenstein-Jensen medium using the absolute concentration method. Sequencing analysis was performed of the rpoB rifampicin resistance-determining region and the katG gene, the oxyR-ahpC intergenic region, and the inhA promoter region in 259 MDR M. tuberculosis isolates, in 51 isoniazid-resistant isolates, and in 13 rifampicin-resistant isolates. The mutational analysis revealed that the most frequent mutations associated with rifampicin and isoniazid resistance in M. tuberculosis are the substitutions at codons 531 (82.7%) and 315 (98.4%) in the rpoB and katG genes, respectively. In addition, we have found mutations with lower frequency at codon 526 (8.4%), 533 (1.5%), and 516 (1.1%) in the rpoB gene. In 6.2% of the isolates, no mutations were found in the rpoB gene. The findings of this study provide useful data for a better understanding of the mutation spectrum of isoniazid and rifampicin resistance among strains isolated from patients in Kazakhstan. Our results are also useful for the development of diagnostic tests of MDR M. tuberculosis.     

应用线性探针技术快速诊断耐多药肺结核效果分析

目的 为验证线性探针技术快速检测耐多药肺结核在基层结核病防治工作中可行性。方法 对459例涂阳肺结核患者痰标本应用线性探针技术快速检测耐利福平、耐异烟肼菌株,同时进行传统罗氏培养和药敏试验结果相比较。结果 线形探针技术与传统药敏试验检测RFP耐药率分别为5.9%(27/459)和6.3%(29/459),差异无统计学意义(χ²=0.038,P＞0.05);INH耐药率分别为8.7%(40/459)和10.0%(46/459),差异无统计学意义（χ²=0.231,P＞0.05）。两种方法检测对RFP均敏感者427例,均耐药者24例,二者结果一致率98.3%（451/459）;对INH均敏感者410例,均耐药者37例,二者结果一致率97.4%（447/459）。两种方法检测耐利福平的灵敏度为82.8%（24/29）,耐异烟肼的灵敏度为80.4%（37/46）,耐利福平、异烟肼特异度均为99.3%（427/430）。结论 应用线性探针技术检测耐多药肺结核与传统药敏试验相比,利福平、异烟肼耐药检出率差异无统计学意义。其特异度高,是快速检测耐多药肺结核的诊断方法。     

Multiple mutations in katG and inhA identified in Thai isoniazid-resistant Mycobacterium tuberculosis isolates

A total of 29 Thai multi-drug-resistant/isoniazid-resistant Mycobacterium tuberculosis isolates were analyzed for mutations in katG from codons 254 to 549, inhA promoter and inhA open reading frame by DNA sequencing and single strand conformation polymorphism. Twenty-five multi-drug resistant isolates exhibited single point mutations (17 isolates at Ser315Thr plus Arg463Leu, 1 at Thr308Pro plus Arg463Leu, 7 at either Ser315Thr or Arg463Leu) while the other 4 isoniazid-resistant isolates had single point mutation only at Arg463Leu. Seven of 25 multi-drug-resistant isolates [4 at C(-15)T, 1 at T(-8)C; 1 at C(-15)T plus Ser94Ala and 1 at Ile21Val] and 2 of 4 isoniazid-resistant isolates [1 at C(-15)T, 1 at C (-15)T plus Ile21Thr] had mutations in inhA promoter and open reading frame, while the other 20 isolates had no mutation at any position. No frame shift mutation was observed in any tested isolates. This is the first report of two mutations, Trp308Pro of katG and T (-8)C of inhA in Mycobacterium tuberculosis isolates.     

Isolation of Burkholderia cenocepacia J 2315 from non-cystic fibrosis pediatric patients in India

We report for the first time 2 cases of multidrug-resistant Burkholderia cenocepacia J2315 isolated from blood samples of patients without cystic fibrosis from a pediatric unit in a hospital in India. The first patient presented with community-acquired bacteremia, and the second patient was immunocompromised and developed hospital-acquired infection approximately 17 days after admission. The isolates from both patients were multidrug-resistant and strong biofilm producers. Surveillance cultures identified the secondary sources of the infections, but not the primary sources.     

Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru.

SETTING: Twenty-nine epidemiological unrelated and mostly multidrug-resistant Mycobacterium tuberculosis (MDR-TB) strains from Peruvian patients. OBJECTIVE: To investigate the molecular genetics of MDR-TB strains recovered in a Latin American country. DESIGN: Antimicrobial agent susceptibility testing, major genetic group designation, IS6110 fingerprinting, spoligotyping, and automated deoxyribonucleic acid sequencing of regions of the katG, rpoB, embB, gyrA, and pncA genes with mutations commonly associated with drug resistance. RESULTS: Nineteen isolates were found to be multidrug-resistant by susceptibility testing. IS6110 typing showed that virtually all isolates were unique and therefore had independently acquired drug resistance. Seventy-nine percent of isoniazid-resistant strains had a Ser315Thr amino acid change in KatG. Ninety-five percent of rifampin-resistant isolates had amino acid replacements in the rifampin-resistance determining region of RpoB. Six of 11 ethambutol-resistant strains had EmbB alterations. Eleven pyrazinamide-resistant strains had distinct mutations in pncA. CONCLUSION: Virtually all organisms evolved drug resistance independently. The types of drug resistance-associated mutations identified were very similar to changes occurring in isolates from other areas of the world. Nucleotide sequence-based strategies for rapid detection of drug resistance-conferring mutants will be applicable to organisms recovered in Peru, and potentially other areas of Latin America.     

Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling "strain W" among noninstitutionalized, human immunodeficiency virus-seronegative patients.

Since 1990, several outbreaks of multidrug-resistant tuberculosis (MDR-TB) have been described among institutionalized patients infected with human immunodeficiency virus (HIV). We describe a community MDR-TB outbreak among HIV-seronegative patients in Cape Town, South Africa. Isolates were characterized by restriction fragment length polymorphism (RFLP) analysis and dot-blot hybridization analysis of mutations conferring resistance for isoniazid, rifampin, streptomycin, and ethambutol. All isolates were identical on RFLP analysis. In 2 patients, RFLP analysis showed exogenous reinfection during or after treatment for drug-susceptible TB. Mutation analysis confirmed the genotypic identity of the isolates. The infecting strain was genotypically related to strain W, which is responsible for the majority of MDR-TB outbreaks in New York City. Transmission of MDR-TB is thus not limited to HIV-seropositive patients in an institutional setting but occurs within a community.     

Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.

SETTING: In 1992 the Seattle-King County Department of Public Health Tuberculosis Clinic began to treat patients with isoniazid-resistant tuberculosis with a regimen of isoniazid, rifampin, pyrazinamide, and ethambutol daily for 6 months. OBJECTIVE: To conduct a review of clinical and bacteriological outcomes of treatment for patients who received the four-drug, 6-month regimen for isoniazid-resistant tuberculosis. DESIGN: A retrospective review of medical records of TB cases meeting the study criteria, a Mycobacterium tuberculosis isolate resistant to isoniazid, and intent to treat with a 6-month course of isoniazid, rifampin, pyrazinamide, and ethambutol. RESULTS: Through December 1999, 44 consecutive patients with isoniazid-resistant, rifampin-susceptible tuberculosis were started on the four-drug, 6-month daily regimen. Among 42 patients followed until completion of therapy, three required changes in the regimen due to side effects. There was one case of drug-induced hepatotoxicity. Among 39 patients with pulmonary involvement, 37 converted sputum cultures from positive to negative within 2 months of starting treatment. There were no treatment failures. On passive follow-up of at least 2 years on all patients, two patients relapsed. The single patient with bacteriological relapse did not develop further drug resistance. CONCLUSION: The regimen of isoniazid, rifampin, pyrazinamide, and ethambutol given daily for 6 months produced successful outcomes when used in a public health tuberculosis clinic as routine therapy for isoniazid-resistant tuberculosis.     

Evidence for local transmission and reactivation of tuberculosis in the Toronto Somali community

To further understand the molecular and clinical epidemiology of tuberculosis in the Toronto Somali community, molecular fingerprinting using IS6110 restriction fragment length polymorphism typing or spoligotyping was performed on M. tuberculosis isolates obtained from Somali-Canadians who developed active disease from 1997 to 2001. Molecular fingerprints were further compared with those obtained from Somalis residing in Denmark. 142 Somali TB patients were reported, for whom, 80 isolates were fingerprinted. 25% of isolates were clustered. Three clusters involving 2 patients each were identified out of the17 isolates that underwent spoligotyping. Of the 63 isolates typed by the IS6110 method, 6 clusters (4 of 2 patients and 2 of 3 patients) were identified. 57% of these isolates were found to be identical to Danish isolates. Our study suggests that a combination of reactivation and recent transmission are responsible for the high incidence rates of tuberculosis in this community. We recommend that ongoing surveillance and treatment programmes be directed towards this community.     

Clinical and programmatic mismanagement rather than community outbreak as the cause of chronic, drug-resistant tuberculosis in Buenaventura, Colombia, 1998.

SETTING: Buenaventura, Colombia. OBJECTIVE: To assess whether antituberculosis drug resistance was generated by poor management or community transmission. DESIGN: Treatment-failure and new tuberculosis (TB) patients identified between May 1997 and June 1998 were interviewed and their treatment histories reviewed. Bacteriologic testing, including drug susceptibility profiles (DSP) and DNA fingerprinting by restriction fragment length polymorphism (RFLP), was performed and human immunodeficiency virus (HIV) testing was offered. RESULTS: DSP and RFLP fingerprints were obtained for isolates from 34 of 64 treatment-failure patients; 25 (74%) were resistant to > or = one drug. Fifteen of the 25 patients consented to HIV testing; none were positive. An average of 2.8 major treatment errors per patient was identified. RFLP from the treatment-failure patients revealed 20 unique isolates and six clusters (isolates with identical RFLP); 4/6 clusters contained isolates with different DSP. Analysis of the RFLP from both treatment-failure and new patients revealed that 44/111 (40%) isolates formed 18 clusters. Four of 47 (9%) new patients had multidrug-resistant TB (MDR-TB). Eleven isolates belonged to the Beijing family, related to the MDR strain W. CONCLUSION: Drug resistance in Buenaventura results from both poor management and community transmission. Dependence on DSP to identify TB transmission is inadequate when programmatic mismanagement is common.     

结核分枝杆菌对异烟肼和利福平的耐药水平与其耐药基因突变的相关性研究

目的 探讨Mtb耐药相关基因katG、inhA、oxyR-ahpC突变与对INH的耐药水平及rpoB突变与对RFP的耐药水平的关系。 方法 采用微孔板Alamar blue显色法分别检测59株耐INH的Mtb临床分离株对INH和30株耐RFP菌株对RFP的最低抑菌浓度（the minimum inhibitory concentration,MIC）,同时用直接测序法检测对INH耐药菌株katG、inhA、oxyR-ahpC和对RFP耐药菌株rpoB的突变情况。 结果 INH MIC为0.2500~1.0000 μg/ml（低水平耐药菌株）和 MIC≥2.0000 μg/ml（高水平耐药菌株）的INH耐药株,inhA启动子突变率前者高于后者［53.8% (7/13),4.3% (2/46)］,katG 315突变率前者低于后者［15.4% (2/13),76.1% (35/46)］,χ²值分别为15.57和13.48,P值均为0.000。RFP MIC为0.5000～16.0000 μg/ml和MIC≥32 0000 μg/ml的RFP耐药株,rpoB 531和526位总突变率前者低于后者［62.5% (5/8),95.5%(21/22)］,P_确切概率＝0.048。 结论 INH耐药菌株inhA启动子突变与INH低水平耐药有关,katG 315突变与INH高水平耐药有关;rpoB 531和526位突变与RFP高水平耐药有关。     

A clinic-based molecular epidemiologic study of tuberculosis in Monterrey, Mexico.

SETTING: A tuberculosis clinic associated with a university hospital in Monterrey, Mexico, an urban community with high tuberculosis incidence. OBJECTIVE: To determine the diversity of DNA fingerprint patterns and the extent of drug resistance of Mycobacterium tuberculosis isolates from patients who attended the clinic. DESIGN: Isolates of M. tuberculosis obtained from 186 patients during the period from 31 January 1996 to 31 March 1998 were tested for susceptibility to isoniazid, rifampicin, ethambutol and streptomycin. Demographic data and the social history of each patient were obtained prospectively by interview. The IS6110 DNA fingerprints were obtained for 166 of the 186 isolates. Secondary typing was carried out on isolates with fewer than six copies of IS6110. RESULTS: Thirty-two per cent of the tested isolates (60/ 186) were drug-resistant, and 18% (33/186) were multidrug-resistant. Approximately 55% of the resistant isolates (33/60) were attributed to acquired resistance. A total of 106 different IS6110 fingerprint patterns were observed among the 166 fingerprinted isolates. Based on both IS6110 and pTBN12 fingerprinting, 65 (39%) of the 166 isolates were part of 22 DNA fingerprint clusters. Various drug susceptibility patterns were seen in most clusters. CONCLUSION: Fingerprint clustering indicates extensive recent transmission of tuberculosis in patients attending the clinic. The prevalence of drug-resistant tuberculosis is high.     

耐多药结核分枝杆菌基因突变分析

目的对临床分离的耐多药结核分枝杆菌株进行基因突变分析。方法对耐多药结核分枝杆菌临床分离菌株进行耐药基因的PCR检测,利用基因序列测定方法分析耐药基因突变情况。结果从耐多药结核病（MDR-TB）患者临床分离菌株中快速检测到rpoB、katG、rpsL、embB基因及其突变。耐多药菌株、全耐及单耐利福平分离菌株均检测rpoB基因点突变,突变位点主要为第516、526和531常见密码子,1例MDR-TB出现第479位和第531位密码子同时突变。耐多药菌、全耐菌及单耐异烟肼的菌株均检测有katG基因点突变,突变位点均为第2066位碱基C突变为Go全耐菌和对乙胺丁醇（EMB）耐药的耐多药菌株均检测有embB基因点突变,突变位点均为第306位密码子ATG突变为ACG。全耐菌和对链霉素（SM）耐药的MDR-TB菌株均检测有rpsL基因点突变,突变密码子为CCT突变为CTT,其中从1株对SM敏感的MDR-TB中也检测到突变。全敏感株、标准株及利福平（RIF）、异烟肼（INH）或EMB敏感的耐药株均无rpoB、katG或embB基因突变。结论PCR及基因序列测定可快速检测耐多药结核基因,结核分枝杆菌耐多药性与多个基因突变相关。     

痰耐药结核分枝杆菌embB基因的快速检测及乙胺丁醇耐药机制研究

目的快速检测痰耐药结核分枝杆菌embB基因及了解乙胺丁醇（EMB）耐药的分子机制。方法用PCR方法直接从耐药肺结核患者痰及临床分离菌株扩增embB基因片段,对扩增获得的embB基因片段进行序列测定,比较分析全耐、对EMB敏感的耐多药、对EMB耐药的耐多药、全敏感或标准结核分枝杆菌株之间的基因序列差异。结果于6小时内从耐药肺结核痰中快速检测到embB基因。从所有临床分离菌株均扩增获得847bp片段,序列测定比较发现,全耐菌和对EMB耐药的耐多药菌株均检测有embB基因点突变,突变位点均为第306位密码子ATG突变为ACG,而全敏感株、对EMB敏感的耐多药菌株和标准菌株均未检测到基因突变。结论PCR及序列分析方法可快速、准确检测结核分枝杆菌embB基因及其突变,结核分枝杆菌对EMB的耐药性与embB基因点突变有关。